Aurora Cannabis Inc. (Nasdaq: $ACB) Stock Hub: The Global Medical Cannabis Reset After FY2026

Executive Summary

Aurora Cannabis enters the second half of calendar 2026 as one of the cleaner but still highly debated names in the listed cannabis sector. The company has moved away from the old Canadian recreational cannabis growth story and is now trying to prove that a regulated, medical-first, international cannabis platform can generate more durable margins than the sector’s legacy consumer model.

The latest material update is Aurora’s fiscal 2026 fourth-quarter and full-year report, released on June 11, 2026, together with the company’s annual Form 40-F. The headline numbers look strong on the surface: record annual global medical cannabis net revenue of C$288.6 million, up 18% year over year, and record annual adjusted EBITDA of C$53.8 million, up 32% year over year. Total net revenue for fiscal 2026 was C$320.6 million, compared with C$288.9 million in fiscal 2025.

That is the constructive side of the story. Aurora is not simply burning cash and waiting for U.S. legalization. It has built a meaningful medical cannabis revenue base, with international medical revenue of C$176.5 million in fiscal 2026, up from C$137.0 million in fiscal 2025. In Q4 FY2026, international medical cannabis revenue reached C$48.8 million, supported by higher sales in Europe, mainly Germany, and growth in Poland.

But the story is not one-dimensional. Q4 was weaker than the full-year headline suggests. Adjusted EBITDA fell to C$9.2 million in Q4 FY2026 from C$18.4 million in Q3 FY2026 and C$14.1 million in Q4 FY2025. Free cash flow was only C$0.3 million in Q4, and full-year free cash flow was negative C$14.3 million, versus positive C$10.9 million in fiscal 2025. Aurora also guided fiscal 2027 toward a reset year, with total net revenue expected to decline and adjusted EBITDA expected to be lower than fiscal 2026 because of Canadian medical reimbursement pricing revisions.

That tension is exactly why $ACB remains interesting. The company is cleaner than it used to be, more medical-focused than most cannabis names, and less dependent on the broken Canadian recreational model. At the same time, the stock still carries the scars of the old cannabis cycle: dilution history, sector skepticism, regulatory volatility, price compression, weak retail trust, and the constant need to separate adjusted profitability from IFRS net losses.

The central question for Aurora is no longer whether cannabis can become a hype sector again. The real question is whether Aurora can become a serious, regulated, medical cannabis export and manufacturing platform with enough margin, cash discipline, and international growth to deserve a valuation outside the cannabis graveyard.

Quick Snapshot

Why Aurora Matters Now

Aurora matters now because the company is trying to do something different from the cannabis sector’s failed 2018–2021 playbook.

The old cannabis thesis was built on huge Canadian cultivation capacity, recreational legalization, retail brand expansion, international optionality, and the assumption that large licensed producers would eventually dominate an enormous consumer market. That story mostly broke. Canada became oversupplied, price competition intensified, consumer cannabis margins disappointed, and the capital structures of many cannabis companies became a long-term burden.

Aurora’s current model is much narrower and more disciplined. The company is focusing on medical cannabis, regulated international markets, pharmaceutical-grade manufacturing, EU-GMP certification, proprietary genetics, and direct or indirect access to pharmacy-based medical channels. In other words, Aurora is trying to become less like a consumer packaged goods cannabis stock and more like a specialized medical cannabis supplier.

That is not just a marketing distinction. In FY2026, medical cannabis represented the overwhelming majority of Aurora’s continuing net revenue. In Q4 FY2026, medical cannabis net revenue of C$77.1 million represented 91% of consolidated Q4 net revenue and generated more than 100% of adjusted gross profit before fair value adjustments, because consumer and wholesale bulk cannabis were much weaker contributors.

The medical segment also carries much stronger economics than the consumer business. For fiscal 2026, Aurora reported adjusted gross margin before fair value adjustments of 68% for medical cannabis, compared with 28% for consumer cannabis and only 3% for wholesale bulk cannabis.

That margin gap explains the whole strategic pivot. Aurora is not winding down lower-margin consumer exposure because it has no brands. It is doing so because the medical business is where the company believes the return on capital is higher.

The market’s problem is that this cleaner strategy comes with a reset. Fiscal 2026 proved that Aurora can generate record medical revenue and record adjusted EBITDA. Fiscal 2027 now has to prove that this model can absorb Canadian pricing pressure, maintain international growth, integrate Safari Flower, complete the consumer wind-down, and still protect cash.

The New Aurora: Medical Cannabis First, Not U.S. Legalization First

The most important correction to the old Aurora narrative is that $ACB is not primarily a U.S. legalization trade today.

Aurora’s annual disclosure states that the company does not currently have direct or indirect cannabis investments in the United States. The company also says any future U.S. market strategy must consider state and federal rules and that it is committed to only engaging in activities permissible under both state and federal laws.

That matters because many cannabis stocks still trade around U.S. reform headlines, even when the operating exposure is elsewhere. Aurora may benefit from improved U.S. cannabis sentiment if federal reform, rescheduling, or medical frameworks improve investor appetite for the sector. But the company’s actual business engine is not U.S. plant-touching exposure. The operational engine is Canada plus international medical cannabis, especially Europe and Australia.

This makes Aurora a different kind of cannabis watchlist name. It is not the cleanest way to play U.S. multi-state operator upside. It is not a pure Canadian consumer cannabis story. It is a global medical cannabis execution story.

The company’s FY2026 Annual Information Form describes Germany as one of the largest federally legal medical cannabis markets outside Canada and notes that Germany continues to rely on imports to meet growing demand. Aurora says its German subsidiary has held relevant licenses and permits and has been importing, exporting, and distributing medical cannabis within the European Union since Germany legalized its medical market. The company also says it is one of the top importers and distributors of medical cannabis in Germany and one of only three companies actively producing medical cannabis within Germany.

That German footprint is central to the story. Aurora is not simply exporting opportunistically. It has regulatory infrastructure, distribution, EU-GMP manufacturing capacity, and an existing operating base in the German market.

The FY2026 Numbers: Strong Full Year, Messier Q4

Aurora’s FY2026 report contains two stories at once.

The first story is strong. Full-year total net revenue increased to C$320.6 million, up from C$288.9 million in FY2025. Global medical cannabis net revenue increased to C$288.6 million, up from C$244.4 million. Adjusted EBITDA increased to C$53.8 million, up from C$40.9 million. Adjusted net income increased to C$39.3 million, up from C$27.2 million.

The second story is more complicated. Net loss from continuing operations was C$58.6 million in FY2026, compared with net income from continuing operations of C$27.1 million in FY2025. Total net loss was C$136.0 million, driven in part by discontinued operations, impairment, fair value movements, business transformation costs, and the Bevo-related reset.

FY2026 Revenue Breakdown

The table tells the story. Medical cannabis is rising, international medical is rising faster, consumer cannabis is shrinking, and wholesale bulk cannabis is not the strategic core.

Q4 FY2026: The Warning Inside the Record Year

Q4 FY2026 was not a clean acceleration quarter. Total net revenue was C$84.8 million, up 10% year over year and up 2% sequentially. Medical cannabis net revenue was C$77.1 million, up 14% year over year but only 1% sequentially. Consumer cannabis net revenue fell to C$3.6 million, down 55% year over year.

Adjusted EBITDA fell to C$9.2 million, down 50% sequentially and down 34% year over year. Adjusted net income fell to C$5.6 million, down 52% sequentially and down 63% year over year. Free cash flow was only C$0.3 million, down sharply from C$18.6 million in Q3 FY2026 and C$5.2 million in Q4 FY2025.

This does not destroy the Aurora story, but it changes the tone. The company’s full-year results confirm a real medical cannabis platform. The Q4 trend and FY2027 guidance tell investors not to extrapolate FY2026 adjusted EBITDA in a straight line.

The FY2027 Reset

The most important part of the June 2026 update may not be FY2026 itself. It may be management’s FY2027 outlook.

Aurora said fiscal 2027 total net revenue is expected to decline and be more in line with fiscal 2025 cannabis net revenue, after changes in Canadian medical reimbursement, partially offset by international growth driven by Germany and Poland. The company also guided adjusted gross margin before fair value adjustments to the mid-to-high fifties and said adjusted SG&A should remain broadly in line with the prior year. Most importantly, adjusted EBITDA is expected to be lower than fiscal 2026 because revised reimbursed pricing is expected to pressure net revenue and adjusted gross profit.

This is a major framing point. Aurora’s medical strategy is credible, but FY2027 is not being guided as a simple continuation of FY2026 growth. The company is effectively saying that the portfolio will be cleaner after exiting lower-margin businesses, but the near-term financial optics will be pressured by reimbursement changes and business transition.

For a stock hub, this is the dividing line. The bull case is not “FY2026 was good, therefore FY2027 will automatically be better.” The bull case is that FY2027 may be a reset year, but the reset could leave Aurora more focused, more medical, more international, and better positioned for FY2028. The bear case is that FY2026 was the high-water mark and FY2027 may reveal that medical cannabis pricing and reimbursement are less durable than the market hoped.

That is the real debate.

Business Model

Aurora’s current business can be simplified into three buckets: global medical cannabis, limited residual consumer cannabis exposure, and residual economic exposure to plant propagation after the Bevo transaction.

1. Global Medical Cannabis

This is the core business.

Aurora serves medical markets in Canada, Europe, Australia and New Zealand, with brands that include Aurora, MedReleaf, Pedanios, IndiMed, San Rafael and Whistler Medical Marijuana Corporation. Medical cannabis includes flower, extracts, oils, cartridges, and other patient-focused products depending on the market.

The key difference from recreational cannabis is the channel: physician involvement, pharmacy distribution, reimbursement structures in some markets, stricter product standards, and higher regulatory barriers.

This is why Aurora’s EU-GMP and TGA-GMP capabilities matter. International medical cannabis is not just a commodity flower export market. Regulated medical markets generally require documentation, quality systems, batch consistency, import/export licensing, and compliance with pharmaceutical-grade standards.

2. Limited Consumer Cannabis

Aurora still reported consumer cannabis revenue in FY2026, but this is no longer the center of the story. The company is winding down certain lower-margin Canadian consumer cannabis markets and says it expects to have very limited activity in the Canadian consumer market, with a full wind-down in the coming months.

Consumer cannabis net revenue fell from C$40.0 million in FY2025 to C$23.5 million in FY2026. In Q4 FY2026, consumer cannabis net revenue was only C$3.6 million, compared with C$8.2 million in Q4 FY2025.

The consumer exit reduces near-term revenue, but it may improve business quality if Aurora can redeploy capacity and resources toward medical markets with better margins.

3. Plant Propagation Residual Exposure

Aurora’s plant propagation business is no longer consolidated after the Bevo transaction closed on February 17, 2026. Aurora exchanged its 50.1% ownership interest in Bevo for preferred shares and retained certain financial rights, including a 5% annual dividend on the par value of the preferred shares, distributions tied to eligible Bevo cash flow, and earnout rights connected to the Aurora Sky and Aurora Sun facilities.

This is important because it simplifies Aurora’s reported business but does not eliminate all residual exposure. The company still has economic interests tied to Bevo’s future performance, and its Annual Information Form warns that the realizable value of those preferred shares and earnout entitlements depends on factors outside Aurora’s control.

The market may like the simplification, but investors still need to watch the residual Bevo exposure.

Medical Cannabis: The Core Economic Engine

The strongest part of Aurora’s report is the medical cannabis segment.

For fiscal 2026, medical cannabis net revenue was C$288.6 million, representing roughly 90% of total net revenue. Medical cannabis adjusted gross margin before fair value adjustments was 68% for the year. In Q4, medical cannabis adjusted gross margin was 66%, down from 69% in Q3 and 71% in the prior-year quarter.

That margin remains high, but the direction matters. The company said Q4 medical cannabis margin pressure was affected by product sales mix, third-party sourcing, and strategic price reductions to preserve market share amid increased competition.

Medical cannabis is therefore both the upside engine and the risk center.

International Growth: Germany and Poland Lead the Story

International medical cannabis is the strongest growth engine in Aurora’s portfolio.

International medical cannabis net revenue increased from C$137.0 million in FY2025 to C$176.5 million in FY2026. In Q4 FY2026, international medical cannabis net revenue was C$48.8 million, compared with C$41.0 million in Q4 FY2025. Aurora attributed the year-over-year Q4 increase mainly to higher sales in Poland and Germany, driven by increased patient demand.

Germany is the most important market in this discussion. Aurora describes Germany as one of the largest federally legal medical cannabis markets outside Canada and says the country continues to rely on imported medical cannabis to meet demand. The company also highlights that Germany’s medical cannabis market received a major boost from the 2024 descheduling of medical cannabis.

Aurora’s German business is not theoretical. The company acquired Aurora Germany in 2017, and that subsidiary has been importing, exporting, and distributing medical cannabis in the European Union since German medical legalization. Aurora also says it distributes directly to German pharmacies and indirectly through wholesalers and pharmacies.

Poland is the other major growth marker. Aurora’s FY2026 Annual Information Form notes the launch of proprietary cultivars Farm Gas and Sourdough in Poland in June 2025 and Black Jelly in December 2025, describing Poland as one of Europe’s fastest-growing medical cannabis markets.

The international story is not only about demand. It is about regulated supply. The winners in medical cannabis are not necessarily the companies with the most cultivation capacity. They are the companies that can deliver consistent, certified, compliant product into markets where doctors, pharmacies, regulators, importers, and patients care about reliability.

That is the lane Aurora is trying to occupy.

Germany: Big Opportunity, Real Regulatory Risk

Germany is both Aurora’s biggest opportunity and one of its clearest regulatory risks.

The opportunity is straightforward. Germany is large, federally legal for medical cannabis, import-dependent, and pharmacy-based. Aurora has licenses, distribution, EU-GMP infrastructure, and domestic production exposure in Germany.

The risk is that Germany’s medical cannabis boom has attracted regulatory scrutiny. Any tightening around telemedicine prescriptions, online access, pharmacy distribution, advertising, reimbursement, or import requirements could affect the pace and quality of growth.

For Aurora, this is nuanced. A crackdown on low-friction online prescription models could slow some demand growth and pressure near-term volumes. But it could also favor companies with stronger regulated medical infrastructure, pharmacy relationships, EU-GMP supply, and a more pharmaceutical-style operating model.

Aurora’s own positioning appears aligned with the more formal medical model. The company emphasizes regulatory expertise, EU-GMP supply, pharmacy distribution, and medical channel execution. If Germany moves toward a stricter prescription-and-pharmacy framework, the result may be negative for some online-first demand channels but not necessarily fatal for Aurora’s long-term position.

The key question is whether the market’s growth rate remains strong enough after tighter rules. If Germany becomes more regulated but still expands, Aurora may benefit from quality barriers. If Germany slows materially or reimbursed prices decline, the bull case weakens.

Australia and New Zealand: Growth Market With Competitive Pressure

Australia is another important market, but the signal is mixed.

Aurora has a meaningful presence through MedReleaf Australia and product expansion across medical cannabis formats. In December 2025, Aurora announced that MedReleaf Australia had entered a distribution partnership with Leafio, the wholesale distribution arm of Montu Australia, to expand patient access to Aurora’s medical cannabis products and support healthcare professionals.

In February 2026, Aurora also advanced its medical growth strategy with portfolio expansion in Australia and New Zealand, including new THC flower products, a balanced THC/CBD product, and resin cartridges.

But Australia is not frictionless. Aurora’s Annual Information Form warns that the Australian medical cannabis market has experienced a rapid increase in licensed importers, distributors and competing brands, creating pricing pressure. The company recognized a non-cash impairment charge of approximately C$13.2 million against intangible assets allocated to its Australian cannabis cash-generating unit during FY2026.

Safari Flower Company Acquisition: Capacity for the Medical Export Engine

Aurora’s April 2026 acquisition of Safari Flower Company is one of the most important post-FY2026 events.

Aurora acquired Safari for total consideration of C$26.5 million, subject to customary adjustments. The consideration included C$15 million in cash and 2,417,180 common shares valued at approximately C$11.5 million, plus contingent consideration of C$2 million tied to satisfying certain GMP certifications.

Safari brings a 59,000 square foot EU-GMP certified indoor cultivation and manufacturing facility intended to supply cannabis to key international markets while reducing reliance on third-party purchases.

This deal fits the Aurora thesis almost too neatly. The company is exiting lower-margin consumer cannabis. International medical demand is growing. Germany and Poland need reliable product. Q4 medical margins were pressured partly by third-party sourcing. Safari adds EU-GMP capacity that can support international flower supply.

The acquisition is not risk-free. Aurora paid with cash and shares. Integration matters. Capacity must translate into sellable, compliant, margin-accretive product. But strategically, Safari is not random diversification. It is a direct investment into the medical export engine.

If Safari helps reduce third-party sourcing costs and supports international volume without damaging quality, it can become a meaningful piece of the FY2027/FY2028 story.

Germany Facility Upgrades and EU-GMP Infrastructure

Aurora’s European infrastructure is another key part of the story.

The FY2026 Annual Information Form states that Aurora undertook an expansion project at its Leuna, Germany facility during fiscal 2026 to drive more EU-GMP production capacity. The company says the improvements are expected to increase flower growth capacity, improve product quality, and drive cost efficiency.

Aurora expects the project to be completed in the first half of fiscal 2027 and, combined with proprietary cultivars, to double the site’s annual flower output. This is one of the most concrete FY2027 operational catalysts.

If the Leuna upgrades are completed successfully, Aurora can strengthen its local European manufacturing base. That could matter for Germany, broader EU supply, cost control, and regulatory credibility.

However, this is also a capital allocation test. Aurora’s cash flow statement shows increased investing cash use in FY2026 partly related to short-term investments and property, plant and equipment purchases, including Leuna upgrades.

The market will want to see whether this investment produces real revenue, better margins, and lower reliance on third parties, not just higher capital intensity.

Science, Genetics and IP: A Less Obvious Differentiator

Aurora is also trying to build differentiation through genetics and plant science.

The company’s FY2026 Annual Information Form notes progress in powdery mildew resistance research. Aurora says it identified a novel source of genetic resistance known as PM2 and performed multiple rounds of crosses to transfer that resistance into elite breeding lines. If production trials are successful, Aurora expects to commercialize PM-resistant cultivars, potentially protecting plant health, reducing operating costs and improving product quality.

Aurora also secured EU Community Plant Variety Rights for two proprietary cannabis varieties during fiscal 2026, strengthening the company’s intellectual property portfolio around proprietary cultivars.

This is not the kind of catalyst retail traders usually chase, but it matters in a medical cannabis model. If Aurora can improve yields, disease resistance, consistency, potency, and product quality through proprietary genetics, the result could be stronger margins and better supply reliability.

The risk is that IP and genetics are hard for the market to value. They sound good, but the market will ultimately want evidence in gross margin, cultivation cost, yield, product demand, and international sell-through.

Balance Sheet

Aurora’s balance sheet is one of the better parts of the story.

The phrase “no debt” used in Aurora’s release should be read carefully. Aurora had no conventional loans and borrowings at fiscal year-end, but it still had lease liabilities and other obligations. That distinction matters for conservative readers. The balance sheet is strong relative to many cannabis peers, but “no debt” does not mean “no obligations.”

The balance sheet also gives Aurora flexibility. The company can fund operations, capacity expansion, and selective acquisitions without immediate financial distress. But the negative FY2026 free cash flow and the FY2027 EBITDA reset mean investors should still monitor cash conversion closely.

Dilution and Share Count

Aurora has a long history of dilution, reverse splits, and capital structure pain. That history is one reason the market still discounts the name heavily.

As of March 31, 2026, Aurora had 58,947,593 common shares outstanding. During FY2026, the company issued 2,210,785 shares through equity financing and received C$10.9 million of proceeds from share issuance, with C$1.6 million of share issuance costs.

On February 4, 2026, Aurora filed a prospectus supplement establishing an at-the-market program allowing the company to issue and sell up to US$100 million of common shares from treasury. The company said proceeds would be used only for strategic and accretive purposes, including cultivation capacity and potential M&A.

After fiscal year-end, the Safari acquisition added 2,417,180 common shares as part of the consideration.

Free Cash Flow: The Metric That Matters Most

Adjusted EBITDA is useful, but free cash flow is more important.

Aurora reported adjusted EBITDA of C$53.8 million in FY2026, but free cash flow was negative C$14.3 million. In Q4, adjusted EBITDA was C$9.2 million, while free cash flow was only C$0.3 million.

This gap is not automatically alarming because FY2026 included restructuring, working capital investment, capex and transition costs. But it prevents the story from being too clean.

The market will likely reward Aurora only if adjusted EBITDA increasingly converts into cash. For FY2027, that may be difficult because the company is guiding lower adjusted EBITDA and still digesting the consumer exit, reimbursement changes, Safari integration, and capacity investments.

Until that happens, the stock remains a reset story rather than a fully proven compounder.

Management and Governance

Aurora is led by Executive Chairman and CEO Miguel Martin and CFO Simona King. Martin’s current strategic message is consistent: Aurora is focused on global medical cannabis, regulatory expertise, EU-GMP supply, and disciplined execution. In the FY2026 release, he stated that the company exceeded its projection for global medical cannabis net revenue and delivered record adjusted EBITDA, validating the global medical cannabis strategy.

Governance deserves a balanced view.

On one hand, Aurora has simplified the business, exited or de-emphasized weaker segments, divested Bevo control, focused on medical cannabis, and maintained a stronger balance sheet than many cannabis peers.

On the other hand, the FY2026 annual report includes an adverse opinion on internal control over financial reporting. Ernst & Young stated that Aurora did not maintain effective internal control over financial reporting as of March 31, 2026 because of a material weakness related to controls over the completeness and accuracy of inputs to significant estimates, assumptions and formulas in certain significant accounts. The auditor also stated that this material weakness did not affect its unqualified opinion on the FY2026 consolidated financial statements.

The correct framing is simple: management has improved strategic focus, but internal control remediation should remain on the watchlist.

Market Setup

ACB remains a damaged cannabis-sector equity. The stock trades far below historical cannabis mania levels and remains under the heavy shadow of prior dilution, reverse splits, sector disappointments and weak retail trust.

That price action reflects two things at once. Cannabis stocks remain out of favor, and the market is not yet willing to pay a premium for Aurora’s medical cannabis reset.

From a watchlist perspective, the stock needs more than “good FY2026 headlines.” It likely needs confirmation that FY2027 guidance is conservative enough, medical margins are defensible, Germany and Poland growth continues, and free cash flow improves after the reset period.

The setup is therefore catalyst-driven but not binary. There is no single FDA-style event. The stock will likely respond to sequential evidence: quarterly revenue mix, international sales, margin stability, ATM activity, cash flow, and management tone around FY2027.

Retail Sentiment

Retail sentiment around Aurora remains mixed. The company has a better story than many cannabis names, but trust in the sector is still low after years of capital destruction.

On social platforms such as Reddit, Stocktwits and X, Aurora is often discussed through two conflicting lenses. The positive camp focuses on medical cannabis revenue, international growth, Germany, the balance sheet, Safari capacity and the consumer exit. The skeptical camp focuses on dilution history, falling Q4 EBITDA, FY2027 guidance, negative free cash flow, and the broader failure of the listed cannabis sector to sustain past rallies.

This matters because Aurora does not only need operational improvement. It also needs the market to believe that this version of the company is structurally different from the old cannabis bubble version.

Key Catalysts to Watch

1. Q1 FY2027 Results

The next major financial catalyst is Q1 FY2027 earnings. This quarter matters because it will be the first real look at the FY2027 reset. Investors will want to see how reimbursement changes, consumer wind-down, Safari, Germany, Poland and margin pressure actually appear in the numbers.

2. FY2027 Revenue and EBITDA Trajectory

Management guided total net revenue lower and adjusted EBITDA lower for FY2027. The market will now test whether the reset is manageable or worse than expected.

3. Germany and Poland Growth

Aurora’s international medical growth depends heavily on Germany and Poland. Investors should track whether these markets continue to offset Canadian pricing pressure.

4. German Regulatory Changes

Any final German rules around telemedicine prescriptions, mail-order distribution, pharmacy dispensing, advertising, or reimbursement could move sentiment.

5. Leuna Facility Upgrade Completion

Aurora expects its Leuna, Germany expansion project to be completed in the first half of fiscal 2027 and, together with proprietary cultivars, to double the site’s annual flower output.

6. Safari Integration

Safari needs to become more than acquired capacity. The market will want evidence that the acquisition helps supply international demand, reduces third-party reliance, supports margin stability, and does not add operational complexity.

7. ATM Usage

The US$100 million ATM program is a permanent watch item. Limited, strategic, accretive use may be accepted. Heavy issuance at depressed prices would be a red flag.

8. Free Cash Flow

The most important medium-term catalyst is not revenue. It is cash conversion. Aurora needs to show that medical cannabis adjusted EBITDA can become durable free cash flow.

Bull Case

The bull case for Aurora is that the company has already made the painful strategic pivot that many cannabis peers still need to make.

Aurora is focused on medical cannabis, not low-margin recreational volume. It has a strong international footprint, especially in Germany and Poland. It has EU-GMP infrastructure, a German production base, Australian and New Zealand exposure, a medical brand portfolio, genetics work, and a balance sheet with substantial cash and no conventional debt at fiscal year-end. It has also deconsolidated Bevo and is winding down lower-margin Canadian consumer cannabis, simplifying the business around the highest-return opportunity.

If FY2027 is only a reset year and not the start of a new deterioration cycle, Aurora could emerge cleaner. In that scenario, Germany and Poland keep growing, Safari adds needed EU-GMP capacity, Leuna expansion improves European output, medical gross margins remain strong enough, and adjusted EBITDA begins converting into positive free cash flow again.

The market capitalization remains modest relative to the company’s medical cannabis revenue base and cash position, which is why the stock can move sharply when sentiment improves. But the bull case requires execution, not just sector optimism.

Bear Case

The bear case is that Aurora’s medical cannabis reset may not be as durable as it appears.

Q4 FY2026 already showed margin pressure, lower adjusted EBITDA, weaker free cash flow and higher adjusted SG&A. FY2027 guidance calls for lower total net revenue and lower adjusted EBITDA because of reimbursed pricing changes. Germany may tighten access rules. Australia is competitive enough that Aurora recorded an impairment charge. Consumer cannabis wind-down may create further costs. Safari integration may take longer than expected. The ATM program may dilute shareholders if the company decides it needs more capital for capacity or M&A.

The deeper bear argument is that medical cannabis may still behave like a competitive commodity business over time, even in regulated markets. If price compression spreads from consumer cannabis into medical markets, the margin advantage may narrow. If reimbursement systems become more restrictive, revenue growth may slow. If Aurora cannot turn adjusted EBITDA into free cash flow, the valuation discount may persist.

The bear case does not require Aurora to fail. It only requires the company to remain “better than before, but not good enough” for the market to re-rate the stock.

Red Flags

• Internal control material weakness: FY2026 audit included an adverse opinion on internal control over financial reporting.
• Regulatory exposure: Germany, Canada, Australia and other medical markets can change rules, reimbursement, distribution models and pricing frameworks.
• Sector sentiment: Cannabis remains a heavily damaged equity sector. Even improved execution can be ignored for long periods if cannabis sentiment stays weak.

Green Flags

• Clear strategic focus: Aurora is exiting lower-margin Canadian consumer cannabis and focusing on global medical cannabis.
• EU-GMP capacity expansion: Safari adds a 59,000 square foot EU-GMP certified facility, while Leuna upgrades are expected to increase German output.
• Genetics and IP: Aurora is developing proprietary cultivars and disease-resistant genetics that may support future cost and quality advantages.

Scenario Framework

Bottom Line

Aurora Cannabis is no longer the same story that defined the old cannabis bubble.

The company has become a focused global medical cannabis operator with meaningful revenue, strong medical gross margins, international growth, EU-GMP infrastructure, a better balance sheet, and a clearer strategic identity. The FY2026 results prove that the medical cannabis platform is real.

But the stock is not a simple recovery story. Q4 FY2026 was weaker than the full-year headline. FY2027 guidance signals a reset. Free cash flow was negative for the year. The company still carries dilution risk, regulatory risk, internal-control remediation risk, and the heavy burden of cannabis-sector skepticism.

The cleanest way to frame $ACB is this: Aurora is not waiting for a U.S. legalization miracle. It is trying to build a regulated global medical cannabis export and manufacturing engine. If FY2027 is merely a reset year before cleaner growth resumes, the stock could deserve renewed attention. If FY2027 reveals that medical cannabis margins are also vulnerable to pricing pressure and reimbursement compression, the market may keep treating ACB like just another damaged cannabis name.

For now, Aurora belongs on the watchlist because the story is finally concrete. But the next proof has to come from execution, not narrative.

Primary Source Base

• Aurora Cannabis FY2026 Q4 and full-year results, June 11, 2026
• Aurora Cannabis FY2026 Form 40-F
• Aurora Cannabis FY2026 MD&A
• Aurora Cannabis FY2026 Annual Information Form
• Aurora Cannabis FY2026 audited consolidated financial statements

All financial figures are reported in Canadian dollars unless otherwise stated. Non-GAAP and adjusted metrics should be read together with the company’s reconciliations and definitions in its official filings.